MediCool Technologies

Cover Block

Attribute	Value
Name	MediCool Technologies
Tagline	Developing painless therapy to terminate dangerous cardiac arrhythmias, starting with atrial fibrillation. [MediCool Technologies, Feb 2026]
Headquarters	Traverse City, United States
Founded	2015
Stage	Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Seed (total disclosed ~$3,000,000) [PitchBook]

Links

• Website: https://medicooltech.com/
• LinkedIn: https://www.linkedin.com/company/medicool-technologies

Summary and Signal

MediCool Technologies is developing an implantable medical device that uses thermal cooling to terminate cardiac arrhythmias without the pain of electrical shocks [MediCool Technologies, Feb 2026]. Founded in 2015 as a Mayo Clinic spinout, the company is preparing for a U.S. Early Feasibility Study in 2026 [MediCool Technologies, Jul 2026]. Its lead application targets atrial fibrillation, where current treatments rely on painful electrical shocks [Michigan Rise, May 2023].

The founding team combines clinical and technical expertise from the Mayo Clinic, with Dr. Paul Friedman as CTO and Dr. Sam Asirvatham as CMO [MediCool Technologies, Jul 2026]. The company has raised approximately $3 million in total funding, with backing from Mayo Clinic Ventures, Michigan Rise, and the National Science Foundation [PitchBook].

Data Accuracy: YELLOW -- Core product and team details are confirmed by company sources; total funding figure is from a single data provider.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	~$3,000,000 total disclosed

Company Overview

MediCool Technologies was founded in 2015 as an academic spinout from the Mayo Clinic by Dr. Paul Friedman and Dr. Sam Asirvatham [MediCool Technologies, Jul 2026]. The company is headquartered in Traverse City, Michigan [Michigan Rise, May 2023].

Early pre-clinical work was supported by two National Science Foundation SBIR grants [MediCool Technologies, Jul 2026]. A venture capital round in August 2022 provided $2.25 million, bringing total disclosed funding to approximately $3 million [PitchBook]. The company published first-in-human data in the journal Heart Rhythm O2, and its next milestone is the completion of a U.S. Early Feasibility Study in 2026 [MediCool Technologies, Jul 2026].

Data Accuracy: YELLOW -- Core founding and location facts are confirmed by company and investor sources. The 2022 funding round amount is sourced from a single data provider (PitchBook).

The Product and the Stack

The core product is an investigational medical device designed to treat cardiac arrhythmias without the pain of an electric shock. MediCool's system, "Cool Cardioversion," uses thermal cooling of cardiac tissue to terminate atrial fibrillation [MediCool Technologies, Feb 2026]. This represents a departure from the standard of care, which relies on implantable cardioverter-defibrillators (ICDs) that deliver high-energy electrical pulses.

The device is an implantable cardioversion device [Michigan Rise, May 2023]. First-in-human data supporting this mechanism were published in the journal Heart Rhythm O2 [MediCool Technologies, Jul 2026]. The current development focus is on completing a U.S. Early Feasibility Study in 2026 [MediCool Technologies, Jul 2026].

Data Accuracy: GREEN -- Product claims and development status are confirmed by company materials and an investor announcement.

The Market They Are Entering

The pursuit of a painless alternative to electrical cardioversion targets a persistent gap in cardiac care. The company's initial focus is on post-operative atrial fibrillation (POAF). The broader addressable market is defined by the prevalence of atrial fibrillation, which the company cites as affecting over six million patients in the United States [MediCool Technologies, Feb 2026]. The American Heart Association projects the number of U.S. adults with AFib will rise to over 12 million by 2030 [American Heart Association].

Market Segment	Cited Size / Driver
Atrial Fibrillation Patient Pool (U.S.)	>6 million patients
AFib Economic Burden (U.S., annual)	$26 billion
Key Demand Driver	Patient aversion to painful electrical cardioversion

Data Accuracy: YELLOW -- The core patient prevalence figure is company-cited; the economic burden is an analogous market estimate. Demand drivers are corroborated by a neutral third-party interview.

The Competitive Field

MediCool Technologies operates in a segment of cardiac electrophysiology where its thermal-cooling approach competes against established electrical and pharmaceutical incumbents.

• Established Pharmacological Therapies. Antiarrhythmic drugs (AADs) are the standard first-line treatment for POAF [20Fathoms, November 2023].
• Traditional Cardioversion Devices. Implantable cardioverter-defibrillators (ICDs) represent the procedural standard for terminating persistent arrhythmias [Michigan Rise, May 2023].
• Emerging Ablation Technologies. Catheter ablation, particularly pulsed-field ablation (PFA), is a growing segment for treating atrial fibrillation.

MediCool's edge rests on its proprietary scientific approach and academic pedigree. The core intellectual property around thermally cooling cardiac tissue is a first-of-its-kind mechanism [MediCool Technologies, July 2026].

Data Accuracy: YELLOW -- Competitive positioning is inferred from public descriptions of the treatment landscape and standard-of-care alternatives.

Opportunity

The prize for MediCool Technologies is a share of the global implantable cardiac device market. The headline opportunity is to establish a new category standard for pain-free cardioversion, beginning with the treatment of post-operative atrial fibrillation (POAF) [MediCool Technologies, Jul 2026].

Scenario	What happens	Catalyst
POAF Standard of Care	MediCool's device becomes the preferred method for managing atrial fibrillation following cardiac surgery.	Successful completion of the 2026 Early Feasibility Study leading to a larger pivotal trial.
Platform Expansion to Chronic AF	The cooling technology is adapted for long-term, implantable use in patients with persistent atrial fibrillation.	Initial FDA clearance for the POAF indication.

Data Accuracy: YELLOW -- Core opportunity thesis is based on company-stated clinical plans and mechanism of action.

Sources

1. [MediCool Technologies, Feb 2026] MediCool Technologies - Painless therapy to terminate dangerous cardiac arrhythmias | https://medicooltech.com/
2. [MediCool Technologies, Jul 2026] History | https://medicooltech.com/history/
3. [Michigan Rise, May 2023] Michigan Rise Supports Development of Therapy for Atrial Fibrillation (A-Fib) with Investment in MediCool Technologies | https://michiganrise.com/2023/05/15/michigan-rise-supports-development-of-therapy-for-atrial-fibrillation-a-fib-with-investment-in-medicool-technologies/
4. [PitchBook] MediCool Technologies | https://pitchbook.com/profiles/company/233566-93
5. [20Fathoms, Nov 2023] Startup Spotlight: MediCool Technologies | https://20fathoms.org/startup-spotlight-medicool-technologies/
6. [MediCool Technologies, Jul 2026] Team | https://medicooltech.com/team/
7. [LinkedIn] Incredible week for us culminating a massive milestone... | https://www.linkedin.com/posts/jeff-rynbrandt_incredible-week-for-us-culminating-a-massive-activity-7405250348635983872-qVWZ